Rocuronio-sugammadex para el manejo de la terapia electroconvulsiva en el síndrome neuroléptico maligno, a propósito de un caso
| Autor: | Á. Outeiro Rosato, P. Diéguez García, P. Casas Reza, M. Gestal Vázquez, S. López Álvarez |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
Paranoid schizophrenia
business.industry medicine.medical_treatment 030208 emergency & critical care medicine Context (language use) Critical Care and Intensive Care Medicine medicine.disease behavioral disciplines and activities Sugammadex Neuroleptic malignant syndrome 03 medical and health sciences 0302 clinical medicine Anesthesiology and Pain Medicine Electroconvulsive therapy 030202 anesthesiology Anesthesia mental disorders medicine Adverse effect business Antipsychotic Clozapine medicine.drug |
| Zdroj: | Revista Española de Anestesiología y Reanimación. 64:105-107 |
| ISSN: | 0034-9356 |
| DOI: | 10.1016/j.redar.2016.04.006 |
| Popis: | Neuroleptics are a group of drugs widely used in the treatment of psychotic symptoms. Among their adverse effects is the ability to trigger a neuroleptic malignant syndrome (NMS). The diagnosis of NMS is determined by exclusion, and its initial therapeutic management should be the withdrawal of neuroleptics, the administration of benzodiazepines, and electroconvulsive therapy (ECT). ECT is an effective treatment in these patients, and in those cases with a poor response to treatment with antipsychotic drugs. A review is presented on the treatment options and anaesthetic implications of ECT used to handle a patient diagnosed with paranoid schizophrenia in the context of NMS. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|